Neuroscience this week

Neuroscience This Week: September 20, 2026

Each week Dr. Missios picks a handful of stories, sums them up in plain language and says what he makes of them.

Issue
This issue

September 20, 2026

Brain tumors
Lab work

A metabolite may be fueling the most aggressive brain tumors

Researchers at UT Southwestern found that nearly all high-grade adult gliomas accumulate large amounts of a molecule called guanidinoacetate, or GAA. In lab studies, GAA overstimulated nearby neurons in ways that seemed to help the tumor grow and spread. The finding, published in Cell, points to a possible new metabolic vulnerability in glioblastoma and similar tumors. This is early laboratory work, not a treatment, but it identifies a concrete target that did not exist before. Researchers now need to figure out whether blocking GAA production slows tumors in animals, and eventually in patients.

Dr. Missios's take

Glioblastoma has been outsmarting us for decades, and any new handle on its biology is worth attention. This is a metabolic discovery in the lab, not a drug, so there is real distance between this finding and anything I can offer a patient tomorrow. Still, a mechanism this specific is the kind of lead that sometimes turns into a real target years down the road.

Source: News-Medical Brain Tumor
See it in 3DAsk about this
Brain tumors
Lab work

An old epilepsy drug may slow a lethal childhood brain cancer

Dr. Missios's take

Families facing a diffuse midline glioma diagnosis are told, correctly, that options are scarce and outcomes are grim. Repurposing an already-approved seizure drug is appealing precisely because it could reach a clinical trial faster than a new molecule would, since we already know its safety profile in humans. That said, this is still animal and lab data, and the honest answer for a parent asking about it today is that a pediatric trial has to happen before anyone can call this a treatment.

Stanford researchers found that an existing anti-seizure medication slowed the growth of diffuse midline glioma, a group of aggressive and currently untreatable childhood brain tumors. The drug appears to work by disrupting how tumor cells communicate with surrounding brain tissue, a mechanism separate from its original seizure-control purpose. Because the medication is already FDA-approved and has a known safety profile, it could move toward clinical testing in children faster than a brand-new compound. The work was done in laboratory and animal models of the disease, not yet in children with these tumors. Diffuse midline glioma remains one of the most devastating diagnoses in pediatric neuro-oncology, with very limited treatment options.

Source: News-Medical Stroke
See it in 3DAsk about this
Head injury

Blast exposure in veterans linked to stroke and nerve problems years later

Dr. Missios's take

Veterans and their families have been asking for years whether blast exposure has downstream consequences beyond the initial injury, and this study says yes for stroke and neuropathy specifically. It is an association from records, so it cannot prove that a particular veteran’s stroke came from a blast decades earlier, but the pattern is biologically plausible given what blast forces do to blood vessels and nerves. The practical takeaway is that blast-exposed veterans deserve longer-term neurological follow-up than they typically get.

A study published in Neurology found that military veterans exposed to high-level blasts, from incoming explosives or land mines, had a higher long-term risk of seizures, neuropathy, and stroke compared with veterans without that exposure. The associations held years after the actual blast exposure occurred. The study is observational, meaning it shows a statistical link rather than proof that blasts directly cause these later conditions, but the pattern is consistent with what is known about how blast forces can injure brain tissue and blood vessels. Researchers are calling for closer long-term neurological monitoring of blast-exposed veterans. The findings add to a growing body of evidence that blast traumatic brain injury has consequences that extend well beyond the initial injury.

Source: News-Medical Stroke
Ask about this
Devices and brain-computer interfaces
Early human studies

Brain implant lets paralyzed patients control a full-body digital avatar

Dr. Missios's take

For a patient who has lost both speech and movement, the hope here is obvious: a way to express not just words but tone and gesture. This is still an early trial with two participants and an implanted device that requires surgery, so it sits far from something I could offer routinely. The engineering is real progress, but the road from a working demonstration to a durable, widely available device is long.

Researchers implanted a high-density electrode grid on the brain surface of two people with severe paralysis and showed it could decode both attempted speech and upper-body gestures at the same time. This let participants control a personalized digital avatar that expressed both what they wanted to say and physical gestures like pointing or waving. Training the system on combined speech-and-gesture attempts, rather than each separately, improved accuracy and cut down on false triggers. This is a proof-of-concept study in a small number of participants using an implanted device, not an approved or widely available technology. It represents a step toward richer communication tools for people who have lost both speech and movement.

Source: News-Medical Stroke
Ask about this
Rare and genetic disease
Proven in trials

FDA approves first gene therapy for a rare childhood brain disease

Dr. Missios's take

Families of children with Sanfilippo syndrome have had nothing to offer for decades, so an actual approval, not just a trial, is significant. Gene therapy for a rare neurodegenerative disease is a real category shift, and this drug has cleared the regulatory bar that most candidates never reach. The open questions now are cost, access, and how much difference it makes over years, which we will only learn as more children are treated.

The FDA approved a new gene therapy for Sanfilippo syndrome type A, an ultra-rare inherited disease sometimes called childhood Alzheimer’s because it causes progressive cognitive decline in young children. The condition results from a missing enzyme that leads to toxic buildup in brain cells, causing developmental regression, seizures, and early death. The gene therapy aims to deliver a working copy of the missing gene to slow or halt that decline. This is a landmark approval for an extremely rare disease with no prior effective treatment, though access, cost, and long-term outcomes remain to be seen in the real world. It is a genuinely new category of treatment for children who previously had no options at all.

Source: STAT News
Ask about this
Other
Early human studies

A psychedelic-like drug enters testing for Parkinson’s apathy

Dr. Missios's take

Apathy is one of the most under-discussed symptoms of Parkinson’s, and patients and spouses often describe it as harder to live with than the tremor. That said, this is a brand-new company at the very start of testing, with no human data yet on this specific drug for this specific symptom. It is worth watching, but it is not something to expect in clinic anytime soon.

A new biotech startup is beginning to test a psychedelic-like compound aimed at treating apathy, a common and under-treated symptom of Parkinson’s disease that leaves patients with reduced motivation and emotional flatness. The drug works on brain circuits related to motivation and reward rather than on Parkinson’s underlying movement symptoms. This is an early-stage program, with testing just starting, so there is no efficacy or safety data yet from human trials for this indication. Apathy in Parkinson’s is often overlooked compared with tremor and rigidity, even though patients and caregivers frequently describe it as one of the most disruptive symptoms. If the approach works, it would address a genuine unmet need that current Parkinson’s medications do not target well.

Source: STAT News
Ask about this
Spine and nerve
Lab work

A genetic discovery could reshape how scientists think about nerve repair

Dr. Missios's take

Every patient with a spinal cord or nerve injury eventually asks whether the nerve can grow back, and the honest answer today is usually no, not in any functionally meaningful way. Findings like this rewrite basic biology about how axons find their targets, which matters because our current regrowth strategies are built on incomplete models. It is fundamental science, years if not decades from changing what I can offer someone with a spinal cord injury, but it is the kind of groundwork that real treatments eventually get built on.

Neuroscientists at Brown University found evidence challenging a long-held model of how neurons extend axons, the long fibers that carry electrical signals, to reach their intended targets during development. The discovery involves genes that guide axon growth in ways not previously appreciated. Because axon regrowth is central to recovering function after nerve or spinal cord injury, a better understanding of how axons naturally find their targets could eventually inform new approaches to nerve repair. This work was done in animal or cellular models, not in humans, and it changes basic understanding rather than offering an immediate therapy. It is early-stage science that reframes a fundamental biological question rather than a clinical breakthrough.

Source: News-Medical Spine
Ask about this
Dementia and aging

Newer blood thinners may slow cognitive decline in Alzheimer’s patients with atrial fibrillation

Dr. Missios's take

This is an observational study, not a trial designed to test cognition, so it cannot prove the drug itself protects thinking rather than just reflecting healthier patients being prescribed it. The biology is plausible though: atrial fibrillation causes small silent strokes that add up, and better stroke prevention could mean less accumulated brain injury. For a patient with both Alzheimer’s and atrial fibrillation, this is a reason to have an honest conversation with a cardiologist about anticoagulant choice, not a reason to expect a cognitive cure from a blood thinner.

A study found that Alzheimer’s patients with atrial fibrillation who took newer blood thinners, known as NOACs, experienced slightly slower cognitive decline than those taking warfarin or no blood thinner at all. Atrial fibrillation raises stroke risk, and blood thinners are prescribed primarily to prevent clots and strokes, not to treat Alzheimer’s directly. The cognitive benefit observed here was modest year to year, but researchers suggest it could add up meaningfully over several years of treatment. The study cannot fully rule out that healthier patients were simply more likely to be prescribed NOACs in the first place. It raises the possibility that better stroke prevention itself, by preventing small silent strokes, may help preserve cognition in this population.

Source: ScienceDaily Neuroscience
Ask about this
How close is this to patients? Lab work: tested in cells or animals, not yet in people. Early human studies: first tests in a small number of patients. Proven in trials: shown to work in larger trials, or newly approved. Standard care: already routine treatment or part of a guideline. Tags are a draft for Dr. Missios to review.

News summaries and opinion, not medical advice. Talk to your own doctor about your situation.